Introduction {#S0001}
============

Serum bilirubin is a metabolic end product of heme, which partially reflects the activity of heme oxygenase (HO).[@CIT0001] In addition, bilirubin is a powerful antioxidant, which has been demonstrated to have a potential antioxidant capacity.[@CIT0002],[@CIT0003] The potential mechanism may be attributed to scavenging of reactive oxygen species. Bilirubin also has an anti-inflammatory property based on the inhibition of endothelial adhesion molecules, such as intercellular adhesion molecule-1, vascular cell-adhesion molecule-1, and E-selectin, by tumor necrosis factor-alpha.[@CIT0004] The protective effects of serum total bilirubin (TB) against cardiovascular-related disease and adverse cardiovascular events have been reported in the last decade. Serum TB has been reported to exert a protective effect on hypertension, diabetes mellitus (DM), atherosclerosis, and coronary artery disease (CAD).[@CIT0005]--[@CIT0008] A meta-analysis containing a large population-based sample of 7,222 participants reported that serum TB was inversely correlated with risk of cardiovascular diseases.[@CIT0009] Kim et al found that lower TB may be a predictor of adverse cardiovascular events in patients with CAD patients after primary percutaneous coronary intervention (PCI).[@CIT0010]--[@CIT0012] In patients with hypertensive and acute syndrome X, this inverse relationship between serum TB and adverse cardiovascular events remained.[@CIT0013]--[@CIT0015] Conversely, recent studies found that serum TB concentration was elevated in patients with acute myocardial infarction (MI), and several cohort studies suggested that higher serum TB was associated with adverse outcomes in patients with MI.[@CIT0002],[@CIT0016]--[@CIT0021] Based on bilirubin's anti-inflammatory and anti-oxidative properties, and different effects of serum TB on cardiovascular events in different populations, serum TB has become a heated research issue recently.

Although previous studies have evaluated the impact of the baseline serum TB on in-hospital cardiovascular outcomes after PCI, few studies have examined its influence on long-term follow-up outcomes. Furthermore, most previous studies focused on the relationship between serum TB and outcomes after PCI in patients with acute coronary syndrome (ACS), and limited evidence was available on patients with stable angina (SA). The clinical profiles and pathogenesis have been recognized to differ significantly between patients with ACS and SA. Its influence on clinical outcomes after PCI may also show differences. Our objective was to clarify the association between serum TB at admission and adverse cardiovascular events during follow up, particularly long-term clinical outcomes in patients with ACS and SA undergoing PCI.

Materials and methods {#S0002}
=====================

Population {#S0002-S2001}
----------

Study data were acquired from the Dryad Digital Repository. Our data are accessible in the Digital Repository (<https://datadryad.org/resource/doi:10.5061/dryad.13d31>). All patients were collected from a single high-volume PCI center who performed successful PCI with at least one drug-eluting stent (DES) from July 2009 to August 2011. Full details of the study population and PCI procedures have been reported previously.[@CIT0022],[@CIT0023] Patients in this study were excluded based on the following criteria: (1) age \<18 years; (2) patients with serum TB at admission \>2.0 mg/dL; and (3) missing covariates or follow-up information. The study was approved by the Ethics Committee of the First Affiliated Hospital of Zhengzhou University with a waiver of informed consent. Data were analyzed anonymously in this study.

Baseline data collection {#S0002-S2002}
------------------------

All basic clinical characteristics information was collected at admission, including demographic information, cardiovascular risk factors, medication at discharge, and angiographic and procedural information. Smoking was defined as patients who smoked within the previous 10 years. Diabetes mellitus (DM) was defined as a fasting plasma glucose concentration ≥126 mg/dL or current treatment with hypoglycemic agents. Hypertension was defined as a systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg or use of antihypertensive drugs. Other disease histories were self-reported. Cardiogenic shock was defined as obvious and persistent hypotension (\>30 min) with systolic arterial pressure \<80 mmHg with signs of hypoperfusion due to the dysfunction of the ventricles of the heart.[@CIT0022]

Clinical outcomes {#S0002-S2003}
-----------------

The primary endpoint was a long-term major adverse cardiovascular event (MACE) during a 3-year follow-up. The secondary endpoints included in-hospital and follow-up outcomes. In in-hospital outcomes, cardiovascular death, and nonfatal MI were observed. In long-term adverse outcomes, cardiovascular death, nonfatal MI, target vessel revascularization (TVR), any revascularization, in-stent restenosis, angina, and stroke were observed. MACE was a composite endpoint, defined as cardiovascular death, nonfatal MI, and stroke occurrence. All follow-up information after discharge of recruited patients was obtained through patient visits to the outpatient clinic or readmission or via a telephone interview with patients and their families. Outcome data were entered by trained research personnel, and the occurrence of adverse events was adjudicated by an independent committee not involved in the procedures.

Statistical analysis {#S0002-S2004}
--------------------

All patients were divided into two groups: the high (\>0.60 mg/dL) and low TB groups (≤0.60 mg/dL). The optimal cutoff point (0.60 mg/dL) was determined by receiver operating characteristic curve analysis. Normally distributed, continuous variables were presented as means (standard deviation), and non-normally distributed data were shown as medians \[inter-quartile ranges\]. Categorical variables were shown as percentages. Student *t*-test or Mann--Whitney U test were used to compare continuous variables in two groups. Chi-squared test or Fisher exact test were applied for analyzing the differences in categorical data. Multiple linear regression analysis was used to determine the relationship of serum TB with cardiovascular risk factors, including age, sex, DM, hypertension, heart rate, smoking, atrial fibrillation, heart failure, history of MI, multiple diseased vessels, lesion of left main stem, restenosis lesions, and ACS. The regression coefficient and 95% CI were depicted.

The associations of serum TB with cardiovascular events after PCI were assessed using multivariable logistic regression analysis with adjustment sets as follows: 1) unadjusted; 2) age- and sex-adjusted; and 3) multivariable: additionally adjusted for DM, hypertension, heart rate, smoking, atrial fibrillation, heart failure, history of MI, multiple diseased vessels, lesion of left main stem, restenosis lesions, ACS, triglycerides, statin, and β-blocker. To assess the shape of the association between TB and MACE, we introduced terms with common transformations of TB inclusive of linear, quadratic, logarithmic, categorical (tertiles), and binary (groups as specified above) in multivariable models and used nonparametric restricted cubic splines with four knots defined as the 5th, 35th, 65th, and 95th percentiles of the distribution of TB. The reference value for TB was 0.52 mg/dL (the median value of TB).

We also examined for interaction the effect of TB on various outcomes by clinical presentation (ACS and SA) in the multivariable model and explored the relationship between serum TB and various follow-up outcomes after PCI in two subgroups (ACS and SA) in logistic regression models after adjusting for age, sex, DM, and hypertension. A two-tailed *p*≤0.05 was considered statistically significant. Statistical analysis was conducted using SPSS 24.0 (IBM, Armonk, NY, USA) and SAS software 9.3 (SAS Institute Inc., Cary, NC, USA).

Results {#S0003}
=======

Baseline characteristics {#S0003-S2001}
------------------------

Of 2,533 patients who received successful PCI from July 2009 to August 2011, 31 patients were excluded based on the exclusion criteria. Finally, 2,502 patients were enrolled in this study ([Figure 1](#F0001){ref-type="fig"}). The mean age was 59.9±11.1 years, and 68.0% of the patients were men. Clinical, laboratory, and angiographic information in the total population are listed in [Table 1](#T0002){ref-type="table"}. The mean serum TB level at admission in the high (\>0.60 mg/dL) and low TB groups (≤0.60 mg/dL) was 0.70 mg/dL \[0.60--0.90\] and 0.40 mg/dL \[0.30--0.50\], respectively. Furthermore, 980 patients (39.2%) had serum TB \>0.60 mg/dL. The high TB group had higher initial systolic, diastolic blood pressure, heart rate, fasting blood sugar, creatinine, and uric acid level, and lower triglycerides and left ventricular ejection fraction than the low TB group. In addition, the high TB group tended to have more male patients, a higher percentage of urgent PCI, more co-morbidities, including previous coronary artery bypass graft (CABG), atrial fibrillation, heart failure, and more complex lesions, including bifurcation lesions and ostial lesions compared with the low TB group.Table 1Clinical information, laboratory tests and procedural characteristicsVariableTB\>0.60 mg/dLTB≤0.60 mg/dL*p*-valuen=980n=1,522Age (years)59.7±11.260.1±11.00.258Male, *n* (%)764 (78)938 (61.6)\<0.001**Admission characteristics** Systolic BP (mmHg)107±28.3100.8±27.9\<0.001 Diastolic BP (mmHg)78.1±12.076.6±11.6\<0.001 Urgent PCI, *n* (%)57(5.8)40(2.6)\<0.001 Cardiogenic shock, *n* (%)3 (0.3)1 (0.1)0.142 Heart rate (/min)72.9±11.471.6±10.80.022**Laboratory test** Fasting glycemia (mmol/L)6.1±36±30.004 Creatinine (mmol/L)73±24.172.2±370.001 Uric acid (mmol/L)309.4±95.2299±83.90.007 TB (mg/dL), median\[IQR\]0.7 \[0.6--0.9\]0.4 \[0.3--0.5\]\<0.001 Total cholesterol (mmol/L)4.2±14.3±1.10.145 Triglycerides (mmol/L)1.8±12±1.40.005 HDL-C (mmol/L)1.1±0.31.1±0.30.446 LDL-C (mmol/L)2.7±0.82.7±0.90.100**History of disease**, *n* (%) Stroke51 (5.2)82 (5.4)0.842 Peripheral vascular disease4 (0.4)2 (0.1)0.167 Previous PCI64 (6.5)105 (6.9)0.720 Previous CABG14 (1.4)6 (0.4)0.005 Myocardial infarction103 (10.5)129 (8.5)0.087 COPD11 (1.1)11 (0.7)0.314 Atrial fibrillation28 (2.9)21 (1.4)0.015 Heart failure124 (12.7)169 (11.1)0.030**Risk factors**, *n* (%) Hypertension449 (45.8)780 (51.2)0.008 Diabetes mellitus182 (18.6)333 (21.9)0.046 Smoking334 (34.1)475 (31.2)0.134**Medication**, *n* (%) Aspirin967 (98.7)1,502 (98.7)0.640 Clopidogrel943 (96.2)1,460 (95.9)0.549 β-blocker638 (65.1)1,060 (69.6)0.018 ACEI506 (51.6)835 (54.9)0.483 CCB201 (20.5)390 (25.6)0.003 Statin864 (88.2)1,411 (92.7)\<0.001**Angiographic and procedural characteristics** Total stent length (mm)48.6±30.651.3±33.90.277 Stent diameter (mm)3.1±1.33.1±0.40.056 Stent type, *n* (%)0.760  SES630(64.3)997(65.5)  PES202(20.6)296(19.5)  Mixture148(15.1)229(15.1) 3 or more diseased vessels, *n* (%)231 (23.5)366(24.0)0.749 Location of target lesions, *n* (%)  Left main stem32 (3.3)52 (3.4)0.331  LAD823 (84)1,246 (81.9)0.063  LCX476 (48.6)736 (48.4)0.539  RCA475 (48.5)761 (50)0.326  Coronary bypass graft2 (0.2)2 (0.1)0.180 Total chronic occlusions, *n* (%)143 (14.6)182 (12)0.056 Ostial lesions, *n* (%)129 (13.2)145 (9.5)0.004 Bifurcation lesion, *n* (%)156 (15.9)290 (19.1)0.045 Restenotic lesion, *n* (%)13 (1.3)21 (1.4)0.839**LVEF** (**%**)60.4 (8.5)61.1 (6.8)0.783**Type of patients**0.018ACS798 (81.4)1,294 (85)SA182 (18.6)228 (15)[^1] Figure 1Study population selection.**Abbreviation:** TB, total bilirubin.

In-hospital and follow-up clinical outcomes {#S0003-S2002}
-------------------------------------------

Clinical outcomes following PCI in the total population are listed in [Table 2](#T0003){ref-type="table"}. Over the follow-up period (median, 29.8 months, quartiles, 25.6--34 months); 250 patients (10.0%) experienced MACE. Among them, 114 patients (4.6%) resulted in cardiovascular death, and 117 (4.7%) and 38 (1.5%) patients experienced nonfatal MI and stroke, respectively. The majority of MACE was attributed to nonfatal MI (117 events, 4.6%) and cardiovascular death (114 events, 4.6%). The rates of MACE (12.8% vs 8.2%, *p*\<0.001) and cardiovascular death (6.3% vs 3.4%, *p*\<0.001) in the high TB group were higher than those in the low TB group. With regard to nonfatal MI, TVR, any revascularization, in-stent restenosis, angina, stroke, and all three in-hospital outcomes, no significant differences were found between the high and low TB groups. Clinical outcomes following PCI in ACS and SA patients separately are listed in [Table S1](#ST0001).Table 2In-hospital and follow-up outcomes in total populationClinical outcomesTB\>0.60 mg/dLTB≤0.60 mg/dL*p*-valuen=980n=1,522**In-hospital outcomes, n (%)** Cardiovascular death11 (1.1)7 (0.5)0.055 Nonfatal MI6 (0.6)9 (0.6)0.947 MACE16 (1.6)15 (1)0.153**Follow-up outcomes, n (%)** MACE125 (12.8)125 (8.2)\<0.001 Cardiovascular death62 (6.3)52 (3.4)\<0.001 Nonfatal MI55 (5.6)62 (4.1)0.075 TVR57 (5.8)66 (4.3)0.095 Any revascularization85 (8.7)114 (7.5)0.286 In-stent restenosis62 (6.3)83 (5.5)0.362 Angina112 (11.4)175 (11.5)0.958 Stroke17 (1.7)21 (1.4)0.479[^2]

Covariates of serum TB {#S0003-S2003}
----------------------

In multiple linear regression analysis, serum TB at admission had positive correlation with age (*β*=0.001 and 95%CI: 0.0002--0.002), male sex (*β*=0.078 and 95%CI: 0.051--0.104), hypertension (*β*=−0.024, 95%CI: −0.046 to −0.003), atrial fibrillation (*β*=0.124, 95%CI: 0.047--0.202), heart failure (*β*=0.072, 95%CI: 0.039--0.105; all *p*-values \<0.05); see [Table 3](#T0004){ref-type="table"}.Table 3Factors related to TB by multiple linear regression analysisParameters*β* (95%CI）*p*-valueAge (years)0.001 (0.0002--0.002)0.012Male0.078 (0.051--0.104)\<0.001Diabetes mellitus−0.015 (−0.042--0.011)0.263Hypertension−0.024 (−0.046 to--0.003)0.027Smoking−0.024 (−0.050--0.001)0.063Atrial fibrillation0.124 (0.047--0.202)0.002Heart failure0.072 (0.039--0.105)\<0.001Myocardial infarction history0.021(−0.019--0.061)0.3073 or more diseased vessels−0.016 (−0.041--0.009)0.215Lesion of left main stem−0.048 (−0.107--0.011)0.114Restenosis lesions−0.018 (−0.109--0.074)0.705Heart rate (/min)0.002 (0.0005--0.003)0.002ACS0.008 (−0.023--0.040)0.605[^3]

Association between TB and clinical outcomes {#S0003-S2004}
--------------------------------------------

Associations between serum TB at admission and clinical outcomes following PCI in the total population are listed in [Table 4](#T0005){ref-type="table"}. In follow-up outcomes, serum TB was associated with MACE and cardiovascular death in univariate logistic regression analysis (MACE: OR and 95% CI, 1.63 \[1.26--2.12\], *p*\<0.001; cardiovascular death: OR and 95% CI, 1.91 \[1.31--2.79\], *p*=0.009), and age- and sex-adjusted logistic regression analysis (MACE: OR and 95% CI, 1.60 \[1.23--2.09\], *p*\<0.001; cardiovascular death: OR and 95% CI, 1.94 \[1.32--2.86\], *p*=0.014). This association remained in MACE and cardiovascular death after further adjustment for other cardiovascular risk factors (MACE: OR and 95% CI, 1.60\[1.2--2.10\], *p*\<0.001; cardiovascular death: OR and 95% CI, 1.81 \[1.22--2.70\], *p*=0.003). Serum TB did not show any significant relationship with respect to other clinical outcomes. Besides, after transformation of TB, relationships of linear, quadratic, logarithmic, and categorical (tertiles) TB with MACE in fully adjusted models are shown in [Figure 2](#F0002){ref-type="fig"}. When TB was a categorical variable, a positive association was observed (OR=0.94, 95% CI: 0.56--1.59 for tertile 2 vs tertile 1; OR=1.44, 95% CI: 0.89--2.34 for tertile 3 vs tertile 1). When TB was a continuous, logarithmic, or quadratic variable, a positive association was also observed ([Figure 2](#F0002){ref-type="fig"}). The dose--response relationship between serum TB and MACE is given in [Table 5](#T0006){ref-type="table"}. Restricted cubic spline is shown in [Figure 3](#F0003){ref-type="fig"}, and the risk of MACE increased with an increase of TB (*p* overall=0.025). A nonlinear dose--response relationship between TB and MACE was not found (*p* nonlinear=0.208).Table 4Associations between total bilirubin \>0.60 mg/dL and clinical outcomes in total populationClinical outcomesModel 1Model 2Model 3OR (95%CI)OR (95%CI)OR (95%CI)**In-hospital outcomes** Cardiovascular death2.46 (0.95--6.36)2.64 (1.00--6.93)NA Nonfatal MI1.04 (0.37--2.92)1.10 (0.38--3.14)NA MACE1.67 (0.82--3.39)1.73 (0.84--3.55)NA**Follow-up outcomes** MACE1.63 (1.26--2.12)1.60 (1.23--2.09)1.60 (1.22--2.10) Cardiovascular death1.91 (1.31--2.79)1.94 (1.32--2.86)1.81 (1.22--2.70) Nonfatal MI1.40 (0.97--2.03)1.38 (0.95--2.02)1.40 (0.96--2.06) TVR1.36 (0.95--1.96)1.60 (1.23--2.09)1.26 (0.86--1.85) Any revascularization1.17 (0.88--1.57)1.09 (0.81--1.47)1.12 (0.83--1.51) In-stent restenosis1.17 (0.83--1.64)1.12 (0.79--1.58)1.15 (0.8--1.64) Angina0.99 (0.77--1.28)0.99 (0.77--1.28)1.01 (0.78--1.31)[^4] Table 5Dose--response relationship between total serum bilirubin and long-term MACESerum total bilirubin (mg/dL)MACEOR95% CI0.210.810.50--1.330.440.880.79--0.970.521.0 (Reference)0.61.161.01--1.321.061.411.01--1.97*p* ~overall~0.025*p* ~nonlinear~0.208[^5] Figure 2Correlation of total bilirubin (TB) with major adverse cardiovascular and cerebrovascular events. (**A**) Categorical TB with tertiles; (**B**) binary, continuous, logarithmic and quadratic TB.Figure 3Plot of dose--response relationship between serum total bilirubin and MACE during follow-up (*p* nonlinear=0.208, *p* overall=0.025).**Abbreviations:** CL, confidence limit; MACE, major adverse cardiovascular events.

The association between serum TB at admission and follow-up adverse events in patients undergoing PCI was analyzed separately in patients with ACS and SA ([Figure 4](#F0004){ref-type="fig"}). In subgroup analysis, higher TB was associated with a greater risk of MACE (OR and 95% CI, 1.61 \[1.20--2.17\], *p*\<0.001) and cardiovascular death (OR and 95% CI, 1.89 \[1.22--2.93\]). Although patients with SA did not show any significant relationship between serum TB and outcomes, no significant interaction was detected in any outcomes (all *p* interaction\>0.05).Figure 4Associations between total bilirubin \>0.60 mg/dL and clinical outcomes in ACS and SA patients.**Abbreviations:** ACS, acute coronary syndrome; MACE, major adverse cardiovascular events; MI, myocardial infarction; SA, stable angina; TVR, target vessel revascularization. Logistic regression model adjusted for age, sex, diabetes mellitus and hypertension.

Discussion {#S0004}
==========

The main finding of the present study was that serum TB level at admission was related with MACE and cardiovascular death during a 3-year follow-up with adjustment for age, sex, DM, hypertension, heart rate, smoking, atrial fibrillation, heart failure, history of MI, multiple diseased vessels, lesion of left main stem, restenosis lesions, and acute coronary syndrome. Our study result clearly showed that a high baseline serum TB level was a simple and powerful predictor of long-term MACE and cardiovascular death in patients undergoing PCI regardless of clinical presentation of CAD.

Previous literature demonstrated that increased serum TB may be protective against adverse vascular events under normal condition.[@CIT0001]--[@CIT0003],[@CIT0009]--[@CIT0011],[@CIT0013],[@CIT0014],[@CIT0024]--[@CIT0026] Conversely, recent reports found that initial serum TB was a prognostic marker of no-reflow and in-hospital adverse outcomes in patients with ST elevation myocardial infarction (STEMI) and MI undergoing PCI.[@CIT0002],[@CIT0017]--[@CIT0019],[@CIT0021],[@CIT0027] Sahin et al found that patients with STEMI with higher TB level accumulated in the high SYNTAX score group than the low SYNTAX score group.[@CIT0028] The results involving TB and cardiovascular outcomes may be different between emergent and non-emergent patients, and most studies observed in-hospital outcomes in patients with ACS rather than patients with SA. Therefore, the present study might provide evidence to fully evaluate the association between serum TB and outcomes over a 3-year follow-up in patients with ACS and SA.

One conceivable reason to explain the positive relationship between TB and long-term outcomes after PCI is that higher serum TB level at baseline may be a reflection of more severe disease status. It can be postulated that the elevation of bilirubin may result from inadequate arterial perfusion of liver and hepatic congestion owing to cardiac dysfunction.[@CIT0021],[@CIT0027] Our finding supported this hypothesis because we observed that patients with higher bilirubin concentration tended to be older and had worse co-morbidities, including atrial fibrillation and heart failure, which may cause higher possibility of long-term dismal outcomes after PCI. In addition, recent finding from Htun et al suggested that elevated bilirubin may be a surrogate marker of unstable plaques, which may cause MI, stroke, and death.[@CIT0029]

Another hypothesis that may explain the relationship between serum TB and unfavorable cardiovascular outcomes in patients with ACS is acute stress reaction. An inducible isoform in response to diverse cellular stress, such as oxidative stress, hypoxia, heavy metals, cytokines, and heme oxygenase 1 (HO-1), reflects the extent of inflammatory reaction to myocardial damage. In previous reports, HO-1 was found to be notably upregulated in the myocardium under infarction and pressure overload condition in animal models.[@CIT0030] The study by Okuhara et al demonstrated a positive correlation between HO-1 protein and its end product bilirubin.[@CIT0031] Amanvermez et al also found that oxidative end products in the first hour of patients with ACS were higher than those in the healthy population.[@CIT0032] Therefore, higher serum TB concentration may also represent more serious myocardial damage in the acute period and following poor outcomes. Acute stress reaction may cause an evident correlation between TB and clinical outcomes in patients with ACS. In patients with SA, we also observed that patients with higher TB tended to have a higher risk of MACE, cardiovascular death, and nonfatal MI, although no statistical significance was observed, which may be due to the smaller sample size of patients with SA. In patients with SA, the potential positive relationship between TB and MACE may be attributed to TB as a marker of more severe disease or more severe cardiovascular dysfunction.

Some limitations still need to be considered. First, only serum TB value at admission was assessed in the study. There was no information regarding the dynamic alteration of serum TB level and time points of adverse event occurrence. Confirmation of the time-dependent association between serum TB level and prognosis is impossible. Second, HO-1 and other markers related to oxidative stress were not measured.[@CIT0018] Third, follow-up information obtained through a telephone interview may be an important bias in the data collection. Finally, although multivariable logistic regression analyses were performed, some potential confounding factors may not be adjusted for in our analyses because of the limited sample size.

Conclusion {#S0005}
==========

We conclude that in patients with ACS and SA who underwent PCI, elevated serum TB level was associated with a greater risk of MACE and cardiovascular death. Baseline serum TB may be treated as an indicator of poor outcome after PCI regardless of whether they are patients with ACS or SA. Our findings warrant additional research, particularly in a larger prospective cohort study, to assess the impact of serum TB on long-term adverse cardiovascular events.
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Table S1In-hospital and follow-up outcomes in ACS and SA patientsClinical outcomesACS patientsSA patientsTB\>0.60 mg/dLTB\<=0.60 mg/dL*p*TB\>0.60 mg/dLTB\<=0.60 mg/dL*p*n=798n=1,294n=182n=228**In-hospital outcomes, n(%)** Cardiovascular death9 (1.1)7 (0.5)0.1342 (1.1)0 (0)0.113 Nonfatal MI5 (0.6)6 (0.5)0.6171 (0.5)3 (1.3)0.432 MACE13 (1.6)12 (0.9)0.1513 (1.6)3 (1.3)0.781**Follow-up outcomes, n(%)** MACE99 (12.4)105 (8.1)0.00126 (14.3)20 (8.8)0.079 Cardiovascular death47 (5.9)43 (3.3)0.00415 (8.2)9 (3.9)0.066 Nonfatal MI47 (5.9)57 (4.4)0.1298 (4.4)5 (2.2)0.206 TVR43 (5.4)54 (4.2)0.15214 (7.7)12 (5.3)0.316 Any revascularization67 (8.4)99 (7.7)0.52818 (9.9)15 (6.6)0.221 In-stent restenosis49 (6.1)71 (5.5)0.52513 (7.1)12 (5.3)0.429 Angina96 (12)144 (11.1)0.43516 (8.8)31 (13.6)0.129 Stroke13 (1.6)15 (1.2)0.3644 (2.2)6 (2.6)0.777[^6]

[^1]: **Abbreviations:** ACS, acute coronary syndrome; BP, blood pressure; CABG, coronary artery bypass graft; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; PCI, percutaneous coronary intervention; SA, stable angina; TB, total bilirubin.

[^2]: **Abbreviations:** MACE, major adverse cardiovascular events; MI, myocardial infarction; TB, total bilirubin; TVR, target vessel revascularization.

[^3]: **Abbreviations:** ACS, acute coronary syndrome; TB, total bilirubin.

[^4]: **Abbreviations:** MACE, major adverse cardiovascular events; MI, myocardial infarction; TVR, target vessel revascularization.

[^5]: **Abbreviation:** MACE, major adverse cardiovascular events.

[^6]: **Abbreviations:** ACS, acute coronary syndrome; MACE, major adverse cardiovascular events; MI, myocardial infarction; SA, stable angina; TB, total bilirubin; TVR, target vessel revascularization.
